Clark Nisse V, Rademaker Doortje, Mushinski Avery A, Ajao Mobolaji O, Cohen Sarah L, Einarsson Jon I
Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts.
J Minim Invasive Gynecol. 2017 Sep-Oct;24(6):971-976. doi: 10.1016/j.jmig.2017.05.015. Epub 2017 Jun 6.
To evaluate perioperative outcomes and symptom resolution in women undergoing removal of the Essure device for device-attributed symptoms.
Retrospective case series and follow-up patient survey (Canadian Task Force classification III).
Large academic medical center.
Fifty-two women who underwent laparoscopic or hysteroscopic Essure removal between 2012 and 2016.
Women underwent one of four procedures: laparoscopic hysterectomy (LH) and bilateral salpingectomy (BS), laparoscopic BS and cornuectomy, laparoscopic Essure removal and BS, or hysteroscopic Essure removal and laparoscopic BS.
Fifty-two women who underwent Essure removal were asked to complete a survey regarding symptom resolution and quality of life following the procedure. Thirty-two women (61.5%) responded to the survey. Seventy-five percent (24/32) reported almost total or total improvement in quality of life, 56.3% (18/32) for sex life, 53.1% (17/32) for pelvic pain, and 65.6% (21/32) for daily activities. The majority of women reported some degree of improvement in all four domains queried (87.5%, 28/32). When asked about their symptoms in general, 31.3% (10/32) of women reported ongoing or worse symptoms after Essure removal. All procedures took approximately one hour (mean 65 min, SD 33 min), were associated with minimal blood loss (mean 31 mL, SD 17), and had no perioperative complications.
Essure removal is a procedure that may be effective for treating most women with symptoms attributed to the device. Patients should be counseled that some symptoms may persist or even worsen following surgery.
评估因节育器相关症状而接受取出爱舒丽(Essure)节育器手术的女性围手术期结局及症状缓解情况。
回顾性病例系列研究及随访患者调查(加拿大工作组分类III级)。
大型学术医疗中心。
2012年至2016年间接受腹腔镜或宫腔镜下爱舒丽节育器取出术的52名女性。
女性接受以下四种手术之一:腹腔镜子宫切除术(LH)及双侧输卵管切除术(BS)、腹腔镜BS及宫角切除术、腹腔镜爱舒丽节育器取出术及BS、或宫腔镜下爱舒丽节育器取出术及腹腔镜BS。
要求52名接受爱舒丽节育器取出术的女性在术后完成一项关于症状缓解及生活质量的调查。32名女性(61.5%)回复了调查。75%(24/32)报告生活质量几乎完全或完全改善,性生活改善率为56.3%(18/32),盆腔疼痛改善率为53.1%(17/32),日常活动改善率为65.6%(21/32)。大多数女性报告在所有四个被询问领域均有一定程度改善(87.5%,28/32)。当被问及总体症状时,31.3%(10/32)的女性报告在取出爱舒丽节育器后症状持续或加重。所有手术均耗时约1小时(平均65分钟,标准差33分钟),失血极少(平均31毫升,标准差17),且无围手术期并发症。
取出爱舒丽节育器手术可能对大多数有该节育器相关症状的女性有效。应告知患者术后某些症状可能持续甚至加重。